CureVac

News

GSK and CureVac settle mRNA patent spat with Pfizer/BioNTech

BioNTech's takeover of CureVac seems to have unlocked a resolution to some of the patent litigation swirling around mRNA vaccine technologies.

News

BioNTech to buy rival mRNA firm CureVac for $1.25bn

BioNTech has agreed to buy another specialist in mRNA medicines, fellow German biotech CureVac, for around $1.25 billion.

News

GSK goes all-in on CureVac’s mRNA vaccines

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and

News

BioNTech wins round in CureVac mRNA patent dispute

Shares in CureVac have plummeted after a German court ruled that a patent it holds on mRNA-based COVID-19 vaccines was invalid.

News

CureVac claims advantage in BioNTech patent dispute

A court in Germany has suspended a trial discussing litigation brought against BioNTech and Pfizer by CureVac alleging patent infringement in connection with their mRNA-ba

News

Glass Medicine Vials and botox, hualuronic, collagen or flu Syringe on a white background.

Pfizer, BioNTech's mRNA flu vaccine starts phase 3 testing

The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine developed by Pfizer and BioNTech, which may offer quicker production and greater efficacy t

GSK and CureVac settle mRNA patent spat with Pfizer/BioNTech

BioNTech to buy rival mRNA firm CureVac for $1.25bn

GSK goes all-in on CureVac’s mRNA vaccines

BioNTech wins round in CureVac mRNA patent dispute

CureVac claims advantage in BioNTech patent dispute

Pfizer, BioNTech's mRNA flu vaccine starts phase 3 testing

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

CureVac

Editor's Picks